2:43 AM GMT, Jun 1, 2019
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact email@example.com.
ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts
While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via new strategies.
BioCentury’s fourth annual survey of abstracts at the American Society of Clinical Oncology (ASCO) meeting presents a snapshot of clinical research in cancer, according to a machine learning-based analysis of 4,627 abstracts for mentions of products, indications, targets, modalities or other hot topic terms.
The 2019 analysis documents 31 novel targets and 22 products in first-in-human trials presented at the meeting, as well as trends in two technologies to improve clinical trials and regulatory decisions (see Table: “ASCO 2019 New Targets” and “Clinical Trial and Regulatory Efficiency Get Help from ctDNA, RWE at ASCO19”).
The 2019 analysis documents 31 novel targets and 22 products in first-in-human trials presented at the meeting.
New modalities continue to advance, with nine of the first-in-human products outside of traditional small molecule and antibody modalities (see Table: “ASCO 2019 First-in-Human Abstracts”).
Bispecific antibodies threaten to steal the show. Though the total number of abstracts mentioning bispecifics -- including one tetraspecific compound -- is still less than some other new modalities, the class showed a substantial surge in activity this year over last (see Figure: “ASCO 2019 Modalities”).